Accession Number : AD1032748


Title :   Annual Surveillance Summary: Pseudomonas aeruginosa Infections in the Military Health System (MHS), 2015


Descriptive Note : Technical Report,01 Jan 2015,31 Dec 2015


Corporate Author : NAVY AND MARINE CORPS PUBLIC HEALTH CENTER PORTSMOUTH VA PORTSMOUTH United States


Personal Author(s) : Gierhart,Sarah ; Chukwuma,Uzo


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/1032748.pdf


Report Date : 01 Mar 2017


Pagination or Media Count : 31


Abstract : Pseudomonas aeruginosa is an opportunistic gram-negative bacterium that can cause severe illness in the immunocompromised. Its minimal nutritional requirements allow it to survive and thrive in both community and hospital settings. In 2015, the incidence rate of P. aeruginosa was 32.6 per 100,000 persons per year in the Military Health System (MHS). This rate reflects a 13.6 increase from the weighted historic baseline from the preceding three years. The South and West regions had the highest incidence rates (43.0 per 100,000 persons per year and 39.9 per 100,000 persons per year, respectively), but the South and South Atlantic regions had the highest incidence of multidrug-resistant (MDR) infections (3.8 per 100,000 persons per year and 2.2 per 100,000 persons per year, respectively). Among all MHS beneficiaries, 47.0 of P. aeruginosa infections were healthcare-associated (HA) cases. P. aeruginosa infections were most susceptible to colistin, piperacillin, and doripenem with average susceptibility to all around 95.0 . P. aeruginosa infections did not display 100.0 susceptibility to any tested antibiotic in the MHS in 2015. Continued surveillance of P. aeruginosa is recommended.


Descriptors :   antiinfective agents , wound infections , antibacterial agents , military medicine , microbiology , active duty , MILITARY HOSPITALS , infection control , hospitalizations , military personnel , patient care management , DRUG RESISTANCE , surveillance


Subject Categories : Microbiology
      Military Forces and Organizations


Distribution Statement : APPROVED FOR PUBLIC RELEASE